Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | REN | P00797 | 4/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31293782 | 0.91 | MMP1 (0.58) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL15223637 | 0.88 | ALDH1A1 (0.60) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL10880715 | 0.87 | REN (0.70) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL13020625 | 0.86 | MMP1 (0.56) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL29861393 | 0.86 | MMP1 (0.56) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL15222243 | 0.86 | POLB (0.57) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL17015153 | 0.85 | POLB (0.59) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL15223640 | 0.85 | POLB (0.59) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL19945248 | 0.85 | ITGA4 (0.61) | POLBMAPTTDP1ATMNPSR1 | |
| SCHEMBL19945249 | 0.85 | ITGA4 (0.61) | POLBMAPTTDP1ATMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-02-23 | — | — | US | disclosed |
| EP-4083051-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-114867734-A | Method for synthesizing peptide compound | 中外制药株式会社 | 2022-08-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056969-A1 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | VIP, NGLY1, NPPA | POLB 2650/4885MAPT 2007/4885TDP1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.